Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXL01 to Prevent Recurrence of Clostridioides Difficile Infection
NCT06306014Phase 2Recruiting
- Sponsor
- Hospices Civils de Lyon
- Start
- May 2024
- Primary completion
- Jan 2028
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
A Phase 2 trial of exl01 in Clostridioides difficile infection (CDI), sponsored by Hospices Civils de Lyon. Started May 2024; status: recruiting.
02
Drugs
exl01
03
Conditions
Clostridioides difficile infection (CDI)
Beyond the preview
Go deeper on NCT06306014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06306014.